Table 4.

CMR Results in Survivors Who Received Low-Dose (< 150 mg/m²) or High-Dose (> 350 mg/m²) Anthracyclines, RT Only, or RT Plus Anthracyclines Among Patients Previously Undiagnosed With Cardiotoxicity

Variable	No. of Evaluable Patients	Median	Range	Mean	SD	Expected Mean*	Prevalence Beyond 2 SD of Normal
							No.	%
Ejection fraction (%)
≤ 150 mg/m2 anthracycline, no RT	45	58.5	50.6-67.0	58.1	4.1	63.9	12	27
> 350 mg/m2 anthracycline, no RT	26	55.9	42.4-66.1	55.5	5.7	64.1	9	35
RT only	18	57.2	40.8-68.5	55.3	7.1	64.1	6	33
RT plus anthracycline	19	55.1	41.3-65.5	54.5	5.5	64.1	8	42
Total	108	57.2	40.8-68.5	56.3	5.5	64.0	35	32
End-diastolic volume/body-surface area (mL/m2)
≤ 150 mg/m2 anthracycline, no RT	45	67.9	34.7-100.7	66.0	14.3	83.0	0	0
> 350 mg/m2 anthracycline, no RT	26	80.4	53.5-102.5	77.6	13.5	79.9	1	4
RT only	18	62.8	43.9-88.0	63.7	11.3	78.8	0	0
RT plus anthracycline	19	70.4	52.6-86.9	68.7	8.74	80.7	0	0
Total	108	70.2	34.7-102.5	69.7	13.5	81.2	1	1
Stroke volume, mL
≤ 150 mg/m2 anthracycline, no RT	45	75.1	40.5-121.1	77.5	19.2	96.6	13	29
> 350 mg/m2 anthracycline, no RT	26	85.1	45.6-116.7	81.5	16.8	95.3	4	15
RT only	18	69.0	32.6-105.4	67.8	16.1	96.6	6	33
RT plus anthracycline	19	70.6	44.4-113.1	73.1	16.1	95.3	6	32
Total	108	74.1	32.6-121.1	76.06	18.0	96.1	29	27
Cardiac mass/body-surface area (g/m2)
≤ 150 mg/m2 anthracycline, no RT	45	41.2	29.3-61.9	42.6	8.1	55.5	25	56
> 350 mg/m2 anthracycline, no RT	26	45.7	32.8-73.3	46.2	9.1	59.8	11	43
RT only	18	44.6	32.4-68.9	45.0	10.3	61.4	12	67
RT plus anthracycline	19	43.4	34.4-57.6	45.5	6.5	58.6	4	21
Total	108	43.5	29.3-73.3	44.4	8.5	58.0	52	48

Abbreviations: CMR, cardiac magnetic resonance [imaging]; RT, radiotherapy; SD, standard deviation.

^*Based on normative, age- and sex-stratified CMR data.